ContraVir Pharmaceuticals (CTRV) Shares Down 0%

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV)’s share price fell 0% during mid-day trading on Wednesday . The company traded as low as $0.25 and last traded at $0.26. 2,382,200 shares traded hands during mid-day trading, an increase of 142% from the average session volume of 984,097 shares. The stock had previously closed at $0.26.

A number of research firms have issued reports on CTRV. ValuEngine upgraded shares of ContraVir Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Maxim Group set a $4.00 price objective on shares of ContraVir Pharmaceuticals and gave the company a “buy” rating in a research report on Monday.

The firm has a market capitalization of $22.95, a PE ratio of -0.56 and a beta of 1.92.

An institutional investor recently raised its position in ContraVir Pharmaceuticals stock. Vanguard Group Inc. lifted its stake in shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 17.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,414,475 shares of the biopharmaceutical company’s stock after buying an additional 366,192 shares during the quarter. Vanguard Group Inc. owned about 3.79% of ContraVir Pharmaceuticals worth $1,400,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 6.71% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright and trademark law. The original version of this report can be read at

ContraVir Pharmaceuticals Company Profile

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive News & Ratings for ContraVir Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply